Secretin - Generic Drug Details

What are the generic drug sources for secretin and what is the scope of patent protection?

Secretin is the generic ingredient in three branded drugs marketed by Ferring and Chirhoclin, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Summary for secretin

US Patents:	0
Tradenames:	3
Applicants:	2
NDAs:	3
Drug Master File Entries:	6
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	38
DailyMed Link:	secretin at DailyMed

Recent Clinical Trials for secretin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE4
ChiRhoClin, Inc.	PHASE4
National Hepatology & Tropical Medicine Research Institute	Phase 2/Phase 3

See all secretin clinical trials

Medical Subject Heading (MeSH) Categories for secretin

Gastrointestinal Agents

Hormones

Anatomical Therapeutic Chemical (ATC) Classes for secretin

V04CK	Tests for pancreatic function
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for secretin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chirhoclin	CHIRHOSTIM	secretin synthetic human	FOR SOLUTION;INTRAVENOUS	021256-001	Apr 9, 2004		RX	Yes	Yes
Chirhoclin	SECREFLO	secretin synthetic porcine	FOR SOLUTION;INTRAVENOUS	021136-001	Apr 4, 2002		DISCN	No	No
Chirhoclin	CHIRHOSTIM	secretin synthetic human	FOR SOLUTION;INTRAVENOUS	021256-002	Jun 21, 2007		RX	Yes	No
Ferring	SECRETIN-FERRING	secretin	INJECTABLE;INJECTION	018290-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Secretin Market Dynamics and Financial Trajectory: FDA Status, Competition, Patents, and Commercial Outlook

Last updated: September 1, 2026

Secretin is a niche diagnostic peptide rather than a large pharmaceutical franchise. Its principal approved use is stimulation of pancreatic secretions during pancreatic-function testing. The market is procedure-driven, concentrated among gastroenterology centers and hospitals, and materially smaller than markets for therapeutic gastrointestinal drugs. Public sources do not report standalone Secretin or ChiRhoStim revenue, so the financial trajectory must be assessed through regulatory status, product availability, procedure utilization, reimbursement, and competitive substitution.

What is Secretin used for?

Secretin is a naturally occurring gastrointestinal peptide that stimulates pancreatic bicarbonate and fluid secretion. The FDA-approved drug is used as an adjunct to pancreatic-function testing in adults and pediatric patients, including testing performed with endoscopic collection of duodenal fluid [1].

Secretin is also used in secretin-enhanced magnetic resonance cholangiopancreatography, or S-MRCP, to improve visualization of the pancreatic duct and assess ductal abnormalities. That imaging use is clinically established but is distinct from the FDA-labeled pancreatic-function-testing indication in the United States.

Secretin has also been studied for autism, gastrointestinal motility disorders, pancreatic disease, and other conditions. These uses have not created a material approved therapeutic market. Clinical evidence has not supported secretin as an effective autism treatment, and the commercial market remains tied primarily to diagnostic procedures [2].

What Secretin products are FDA approved?

The main U.S. products have been synthetic human secretin injections marketed for diagnostic use.

Product	Active ingredient	Primary use	FDA regulatory position	Commercial relevance
ChiRhoStim	Synthetic human secretin	Pancreatic-function testing	Approved under NDA 021514	Established branded diagnostic product
SecreFlo	Synthetic human secretin	Pancreatic-function testing	FDA-approved secretin product	Historical or competing supply source
Compounded secretin	Secretin peptide	Variable diagnostic or investigational use	Not equivalent to an FDA-approved commercial product	Limited and institution-specific

ChiRhoStim is associated with ChiRhoChem, Inc. The FDA label identifies the product as secretin for injection and provides dosing instructions for pancreatic-function testing [1]. Product availability and commercial status have changed over time, and institutional procurement records may show a different supplier from the original branded product.

The market is unusually dependent on supply continuity because secretin is used in low-volume diagnostic procedures. A temporary manufacturing or distribution interruption can affect access even when underlying clinical demand remains stable.

What is the Orange Book status of Secretin?

Secretin has limited patent-based exclusivity exposure compared with newer drugs.

The relevant FDA approval is NDA 021514 for ChiRhoStim. The Orange Book is the primary source for determining whether patents and regulatory exclusivity are listed against an approved small-molecule or peptide drug application [3]. Secretin’s commercial history indicates that any original composition-of-matter or approval-related exclusivity has expired.

Exclusivity category	Secretin assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not the principal commercial protection
Pediatric exclusivity	No current material protection identified
Listed formulation patents	No current high-value barrier publicly evident
Method-of-use patents	Limited commercial impact
Regulatory exclusivity	Expired for the mature product
Biosimilar exclusivity	Not applicable in the conventional biologic sense

Secretin is a peptide drug, but it is generally treated commercially as an established injectable diagnostic product rather than as a modern reference biologic with an active biosimilar franchise. A future competitor would more likely pursue an abbreviated or full application strategy based on the applicable FDA pathway than rely on a biosimilar-style commercial model.

When does Secretin lose exclusivity?

Secretin has already lost the exclusivity that would normally support premium branded pricing. Its commercial protection now depends on manufacturing capability, regulatory compliance, product reliability, physician familiarity, distribution access, and reimbursement.

The absence of meaningful current exclusivity creates a low legal barrier but does not automatically produce a large generic market. Demand is limited, clinical use is specialized, and the product requires sterile injectable manufacturing. A prospective entrant must also establish a commercially viable distribution network for a product used in relatively few procedures.

Secretin’s effective market protection is therefore operational rather than patent-based. The most relevant barriers are:

1. Production of a consistent, sterile peptide injectable.
2. FDA approval and validated analytical methods.
3. Reliable cold-chain or controlled distribution, where required.
4. Hospital formulary and purchasing acceptance.
5. Evidence supporting use in pancreatic-function testing.
6. Reimbursement sufficient to support the procedure.

How large is the Secretin market?

No public company reports standalone Secretin revenue, unit volume, or market share. ChiRhoChem is privately held, and public filings do not provide a separate ChiRhoStim revenue line. Repligen’s public reporting has also not established a reliable standalone revenue series for secretin products.

The addressable market is constrained by the number of pancreatic-function tests and secretin-enhanced imaging procedures performed. Secretin is not used chronically. Most patients receive one dose during a diagnostic encounter, which limits recurring prescription volume but creates predictable procedure-linked demand.

Key market-demand drivers

Demand is supported by:

• Evaluation of suspected exocrine pancreatic insufficiency.
• Chronic pancreatitis workups.
• Cystic fibrosis-related pancreatic disease.
• Congenital or structural pancreatic disorders.
• Pediatric gastroenterology testing.
• Secretin-enhanced MRCP at specialized imaging centers.
• Referral-center use when noninvasive tests are inconclusive.

Market-demand constraints

Demand is reduced by:

• Fecal elastase testing.
• Direct pancreatic-function tests that use alternative stimulants or protocols.
• Endoscopic complexity and procedure cost.
• Availability of CT, standard MRI, EUS, and laboratory testing.
• Limited availability of specialized pancreatic-function testing.
• Physician preference for noninvasive diagnostics.
• Reimbursement pressure on diagnostic procedures.

Secretin is therefore a small, stable, specialist market. It is more comparable to an injectable diagnostic reagent than to a conventional gastrointestinal prescription drug.

How does Secretin compare with competing diagnostic approaches?

Diagnostic approach	Secretin requirement	Main advantage	Main limitation
Secretin-stimulated pancreatic-function testing	Required	Direct physiologic assessment of pancreatic secretion	Invasive, specialized, procedure-dependent
Secretin-enhanced MRCP	Required	Improves ductal and functional imaging information	Added drug and imaging cost
Fecal elastase	Not required	Noninvasive and widely accessible	Indirect assessment; limitations in mild disease
Endoscopic ultrasound	Not required	High-resolution structural evaluation	Operator-dependent and invasive
Standard MRI or CT	Not required	Broad availability	Less functional information
Direct pancreatic stimulation with other agents	May use alternative stimulant	Can support physiologic testing	Protocol and availability differences

The principal competitive threat is substitution by non-secretin diagnostics, not a large wave of conventional generic prescriptions. Secretin remains valuable where direct functional testing or enhanced ductal imaging changes clinical management.

What patents protect Secretin and its formulations?

The original secretin molecule is long established, and composition-of-matter protection is not commercially relevant. Any active intellectual-property value would more likely relate to:

• Specific synthetic or purification processes.
• Stabilized injectable formulations.
• Lyophilized dosage forms.
• Container-closure systems.
• Reconstitution procedures.
• Combination diagnostic protocols.
• Imaging methods using secretin.
• Manufacturing controls and analytical specifications.

Publicly visible commercial protection does not indicate a current patent estate capable of blocking all competitors. Formulation patents, if enforceable in a particular jurisdiction, would not necessarily prevent a competitor from developing a different formulation or manufacturing process.

Method-of-use claims may have greater practical relevance in secretin-enhanced imaging or specialized pancreatic testing. Their value remains limited by the narrow procedure population and the difficulty of proving infringement when hospitals and physicians control use.

Which companies are challenging or competing with Secretin products?

The competitive field has included ChiRhoChem and other suppliers of synthetic human secretin, including products associated with Repligen. The market is not characterized by a large number of active generic manufacturers.

Competition occurs through:

• Product availability.
• Hospital contracting.
• Wholesale distribution.
• Regulatory status.
• Batch reliability.
• Unit economics.
• Support for diagnostic protocols.
• Ability to supply low-volume orders without interruption.

No major Paragraph IV litigation campaign is publicly associated with Secretin’s mature U.S. market. That is consistent with the product’s age, limited volume, and lack of valuable remaining patent exclusivity.

What is the Paragraph IV and patent-litigation risk for Secretin?

The current Paragraph IV risk is low because Secretin’s principal commercial protections have expired and the market has limited revenue potential. A future abbreviated-application applicant could still challenge any listed patent, but the economic incentive to litigate would be modest unless the incumbent product achieves higher pricing or supply constraints create an attractive opening.

Potential litigation would more likely involve:

• Product liability.
• Manufacturing quality.
• Contract disputes.
• Distribution rights.
• Trademark or labeling issues.
• Patent claims directed to a specific formulation or use.

There is no widely reported, market-defining settlement agreement involving Secretin comparable to settlements in large oncology, immunology, diabetes, or cardiovascular franchises.

What is the FDA regulatory status of Secretin?

Secretin is an FDA-approved prescription injectable diagnostic product under NDA 021514. The approved product is not a therapeutic treatment for pancreatic insufficiency. Its label focuses on stimulation of pancreatic secretions to support testing [1].

Regulatory risk is concentrated in manufacturing and supply rather than clinical-development risk. The product must meet requirements for:

• Peptide identity and purity.
• Sterility.
• Potency.
• Stability.
• Batch consistency.
• Labeling and dosing.
• Appropriate reconstitution and administration.

Because secretin is administered in a diagnostic setting, adverse events and contraindications remain relevant to hospital protocols. The label identifies hypersensitivity risk and gastrointestinal or systemic adverse reactions associated with secretin administration [1].

How does reimbursement affect Secretin’s commercial trajectory?

Secretin revenue is linked to reimbursement for the underlying diagnostic procedure rather than to prescription volume alone. Hospitals may purchase the drug as part of a bundled or facility-based service. The economic return depends on whether the additional secretin cost is covered, passed through, or absorbed within the procedure payment.

Commercial performance is therefore sensitive to:

• Medicare and commercial reimbursement for pancreatic-function testing.
• Hospital outpatient payment rules.
• Imaging-center utilization.
• Prior authorization.
• Procedure coding.
• Availability of gastroenterologists and specialized testing laboratories.

A decline in direct pancreatic-function testing can reduce secretin demand even if the product itself retains clinical utility. Conversely, increased use of secretin-enhanced MRCP can support demand without increasing conventional pancreatic-function testing.

What is the financial trajectory for Secretin?

Secretin’s financial trajectory is best characterized as mature, low-growth, and supply-sensitive.

Financial factor	Expected effect
Expired exclusivity	Limits premium pricing and supports competitive entry
Narrow diagnostic indication	Caps total addressable market
Low repeat dosing	Reduces recurring prescription revenue
Specialized manufacturing	Supports some price resilience
Limited suppliers	Creates potential short-term pricing power
Noninvasive diagnostic substitution	Pressures long-term volume
Secretin-enhanced imaging	Provides a potential demand-supporting use
Private ownership and limited disclosure	Prevents reliable standalone revenue modeling

The product is unlikely to generate blockbuster economics. Its value is more consistent with a niche hospital product that can produce durable cash flow if manufacturing is reliable and competition remains limited.

The most plausible commercial scenarios are:

Base case

Stable but modest demand from academic hospitals, pediatric centers, pancreatic disease specialists, and selected imaging centers. Revenue remains flat to low-growth, with periodic changes driven by supply and reimbursement.

Upside case

Broader adoption of secretin-enhanced MRCP, increased recognition of exocrine pancreatic dysfunction, or supplier consolidation improves utilization and pricing. The upside remains constrained by the size of the procedure population.

Downside case

Further migration to fecal elastase, EUS, standard MRI, or other non-secretin testing reduces procedure volume. A manufacturing interruption or reimbursement change accelerates the decline.

What generic entry risks exist for Secretin?

Generic entry risk is legally meaningful but commercially moderate. The lack of active exclusivity allows competition, yet the small market may not justify development and launch costs for multiple entrants.

A generic or alternative secretin product would need to overcome:

• Limited annual unit demand.
• Sterile peptide manufacturing requirements.
• FDA quality-system obligations.
• Hospital purchasing inertia.
• Need for dependable supply.
• Narrow clinical use.
• Potentially low return on regulatory investment.

The highest near-term risk to an incumbent is likely a qualified competing supplier rather than rapid multi-generic erosion. If two or more reliable suppliers enter, hospital purchasers could obtain price concessions and the branded product could lose share quickly.

What licensing deals and manufacturing barriers affect Secretin?

Secretin has limited publicly disclosed licensing activity compared with major branded pharmaceuticals. The commercial value lies primarily in product rights, manufacturing, distribution, and regulatory files.

Manufacturing know-how can provide practical protection even when patents do not. Important technical assets include peptide synthesis or recombinant production methods, purification, impurity control, lyophilization, vial filling, sterility assurance, and stability data.

These assets can delay competition but do not create permanent exclusivity. A competitor with an established sterile injectable platform may be able to enter more efficiently than a company building a facility specifically for Secretin.

Key Takeaways

• Secretin is a niche FDA-approved diagnostic peptide, not a major therapeutic drug.
• ChiRhoStim, associated with ChiRhoChem, is the principal U.S. commercial reference product.
• NDA 021514 is the central FDA approval associated with ChiRhoStim.
• Original exclusivity and composition-of-matter protection have expired.
• The Orange Book and patent estate do not indicate a current high-value barrier to entry.
• No major active Paragraph IV campaign or settlement is publicly associated with the mature market.
• Demand is tied to pancreatic-function testing and secretin-enhanced MRCP.
• Fecal elastase, EUS, CT, standard MRI, and other diagnostics limit growth.
• Public companies do not report reliable standalone Secretin revenue.
• The financial outlook is mature and low-growth, with supply reliability and reimbursement driving performance.
• The main commercial risk is entry by a reliable sterile injectable competitor, followed by gradual substitution by non-secretin diagnostics.

Frequently Asked Questions

Is Secretin a biologic drug?

Secretin is a peptide hormone drug. It is commercially handled as an injectable diagnostic product rather than as a large-scale biologic franchise with a meaningful biosimilar market.

Is Secretin approved to treat pancreatic insufficiency?

No. FDA-approved Secretin is used to stimulate pancreatic secretions during diagnostic testing. It is not approved as replacement therapy for pancreatic enzyme deficiency.

Does Secretin have orphan-drug exclusivity?

No current orphan-drug exclusivity is the principal commercial protection for Secretin. Any historical regulatory protection does not materially constrain present-day competition.

Can pharmacies dispense Secretin for home use?

Secretin is generally administered in controlled clinical or hospital settings because it is used as part of a diagnostic procedure. It is not a routine outpatient maintenance medicine.

What is the largest commercial opportunity for Secretin?

The strongest opportunity is expansion of specialized pancreatic diagnostics, particularly secretin-enhanced MRCP and direct pancreatic-function testing at referral centers. The opportunity remains limited by procedure volume and reimbursement.

References

1. U.S. Food and Drug Administration. (2020). ChiRhoStim (secretin) for injection: Prescribing information. FDA Drugs@FDA, NDA 021514.

2. Williams, K., Wray, J. A., & Wheeler, D. M. (2013). Intravenous secretin for autism spectrum disorders: A systematic review. Cochrane Database of Systematic Reviews, 2013(4), CD003495.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA Center for Drug Evaluation and Research.

4. Centers for Medicare & Medicaid Services. (2024). Physician fee schedule and outpatient prospective payment system resources. U.S. Department of Health and Human Services.